Drug Price Trends for NDC 63402-0206

Average Pharmacy Cost for 63402-0206

Drug Name	NDC	Price/Unit ($)	Unit	Date
APTIOM 600 MG TABLET	63402-0206-60	44.22469	EACH	2026-01-01
APTIOM 600 MG TABLET	63402-0206-60	42.93659	EACH	2025-12-17
APTIOM 600 MG TABLET	63402-0206-60	42.93801	EACH	2025-11-19
APTIOM 600 MG TABLET	63402-0206-60	42.95389	EACH	2025-10-22
APTIOM 600 MG TABLET	63402-0206-60	42.97896	EACH	2025-09-17
APTIOM 600 MG TABLET	63402-0206-60	42.97949	EACH	2025-08-20
APTIOM 600 MG TABLET	63402-0206-60	42.98289	EACH	2025-07-23

Best Wholesale Price for NDC 63402-0206

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of Nplate (romiplostim) Patent Landscape and Market Projections

Last updated: February 19, 2026

This report analyzes the patent landscape surrounding Nplate (romiplostim), a thrombopoietin receptor agonist, and projects future market performance. The analysis focuses on key patent expirations, competitive threats, and pricing dynamics.

What is Nplate and What is Its Therapeutic Use?

Nplate is apegylated thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a corticosteroid, a methylprednisolone, or an immunoglobulin. It is also approved for the treatment of thrombocytopenia in adult patients with chronic hepatitis C to allow for the use of interferon-based therapy. Nplate is administered subcutaneously. The active ingredient, romiplostim, is a fusion protein.

What is the Regulatory Status of Nplate?

Nplate (romiplostim) was first approved by the U.S. Food and Drug Administration (FDA) on February 1, 2008, under the New Drug Application (NDA) 021700. It received European Medicines Agency (EMA) approval on September 21, 2009. The drug is marketed by Amgen Inc.

What is the Current Pricing and Market Size for Nplate?

Nplate pricing varies by dosage and formulation. As of early 2024, typical wholesale acquisition costs (WAC) for Nplate (romiplostim) are approximately as follows:

• 250 mcg vial: $1,600 - $1,800 USD
• 500 mcg vial: $3,000 - $3,400 USD

The annual cost of therapy can range from $40,000 to over $100,000 USD per patient, depending on dosage and treatment duration.

The global market for Nplate has been a significant contributor to Amgen's revenue in the autoimmune and inflammatory disease sector. While specific recent market size figures are proprietary, analyst reports from the early 2020s estimated the romiplostim market to be in the range of $1 billion to $1.5 billion annually. This market size is influenced by the prevalence of chronic ITP and the demand for effective treatments that enable concurrent therapy for hepatitis C.

What is the Patent Landscape for Nplate?

The patent protection for Nplate (romiplostim) involves a portfolio of U.S. patents covering composition of matter, manufacturing processes, and methods of use. Key patents and their expiration timelines are critical for understanding future market exclusivity.

Table 1: Key Patents for Nplate (Romipolstim)

Patent Number	Title	Filed Date	Issue Date	Expiration Date (Original)	Status
7,118,725	Peptides comprising amino acid sequences that stimulate megakaryopoiesis	June 19, 2003	October 10, 2006	October 10, 2023	Expired
7,538,097	Peptides comprising amino acid sequences that stimulate megakaryopoiesis	June 19, 2003	May 26, 2009	May 26, 2024	Expired (Pending potential extensions)
7,713,709	Methods for stimulating megakaryopoiesis	July 18, 2005	May 11, 2010	May 11, 2025	Expired (Pending potential extensions)
8,071,557	Combination therapy	March 13, 2008	December 6, 2011	December 6, 2028	Active
8,575,309	Fusion proteins comprising protein domains	September 29, 2009	November 5, 2013	November 5, 2030	Active
9,056,852	Methods for producing fusion proteins	February 27, 2013	June 16, 2015	February 27, 2033	Active

Note: Expiration dates are based on the original patent terms and do not account for potential patent term extensions (PTE) or adjustments (PTA). Detailed analysis of PTE and PTA is required for precise exclusivity end dates.

The U.S. Patent and Trademark Office (USPTO) can grant patent term extensions to compensate for regulatory review delays. For Nplate, PTEs would have been applied for based on the time lost from the effective filing date of the application to the date of approval.

The '725 and '097 patents are foundational, covering the composition of matter for romiplostim. The expiration of these key patents opens the door for generic competition.

What are the Potential Biosimilar or Generic Entry Strategies?

The expiration of the '725 and '097 patents, particularly the '097 patent expiring in May 2024, signifies a critical juncture for Nplate. The potential for biosimilar or generic entry will significantly impact market dynamics.

• Biosimilar Development: Romiplostim is a complex biologic (a fusion protein). The development and approval of biosimilars are governed by a different pathway than generics for small molecules. In the U.S., this is regulated under the Biologics Price Competition and Innovation Act (BPCIA). A biosimilar must be highly similar to the reference product, with no clinically meaningful differences in safety, purity, and potency.
• ANDA Pathway: For small molecule drugs, an Abbreviated New Drug Application (ANDA) is filed. Romiplostim's nature as a biologic means a biosimilar pathway is applicable.
• Patent Litigation: Amgen has historically defended its intellectual property through patent litigation. Companies seeking to launch biosimilars typically engage in legal battles over the validity and infringement of remaining patents, such as the method of use patents or manufacturing patents. The '8071557 patent and others covering manufacturing processes and methods of use remain active, potentially extending market exclusivity through further legal challenges or licensing agreements.
• Market Exclusivity Periods: The BPCIA provides a 12-year data exclusivity period for new biological products, meaning no biosimilar can be approved during this time from the reference product's first commercial marketing. However, this exclusivity is generally for the product itself, not necessarily for specific indications. If romiplostim's initial approval date was February 1, 2008, the 12-year exclusivity would have ended around February 2020. However, for biosimilars, the interplay between patent expiration and statutory exclusivity is complex and often subject to litigation.

As of early 2024, there are no FDA-approved biosimilars for Nplate. The market entry of biosimilars will depend on the successful navigation of regulatory pathways and the resolution of any ongoing patent disputes.

What are the Projected Market Share and Price Erosion Post-Patent Expiration?

The impact of biosimilar entry on Nplate's market share and pricing will be substantial, mirroring trends observed for other biologics.

Table 2: Projected Market Dynamics Post-Patent Expiration

Metric	Pre-Biosimilar Entry (2023-2024)	Post-Biosimilar Entry (2025-2027)	Post-Biosimilar Entry (2028-2030)
Nplate Market Share	95-100%	60-80%	40-60%
Average Selling Price	High (WAC-based)	Declines by 20-40%	Declines by 40-60%
Biosimilar Market Share	0%	20-40%	40-60%
Biosimilar Pricing	N/A	20-30% discount to Nplate	30-45% discount to Nplate

Projections are estimates and subject to significant variation based on the number of biosimilar entrants, their pricing strategies, physician and payer adoption, and ongoing litigation.

Price Erosion Analysis:

• Initial Entry: The first biosimilar entrant typically leads to a price reduction of 15-25% for the reference product.
• Increased Competition: As more biosimilars enter the market, competition intensifies, driving further price erosion. Discounts can reach 30-50% or more of the original product's price.
• Payer Influence: Pharmacy benefit managers (PBMs) and insurance payers play a crucial role. They will negotiate aggressively with biosimilar manufacturers to secure preferred formulary placement, often incentivizing the use of lower-cost biosimilars.

The market share of Nplate is expected to decline significantly as biosimilars gain traction. While Nplate will likely retain a portion of the market due to established physician relationships, brand loyalty, and potential specific indication advantages (if any remain exclusively protected), its dominance will be challenged.

The market size for romiplostim (Nplate and its biosimilars collectively) may see initial growth due to increased access and potentially broader patient eligibility under payer agreements. However, the overall revenue generated by the originator brand will contract sharply.

What are the Key Drivers and Restraints for Future Market Growth?

Key Market Drivers:

• Increasing Prevalence of Chronic ITP: The incidence of Chronic Immune Thrombocytopenia (ITP) remains a consistent driver for therapies like Nplate. Global aging populations and improved diagnostic capabilities contribute to this.
• Demand for HCV Therapy Enablers: While direct-acting antivirals (DAAs) have largely revolutionized Hepatitis C treatment, leading to a significant reduction in the need for interferon-based therapies and thus Nplate for this indication, a residual patient population or specific treatment protocols may still necessitate its use.
• Clinical Effectiveness: Nplate's proven efficacy in raising platelet counts and enabling treatment continuation for patients with ITP and HCV is a foundational driver.
• Biosimilar Adoption: The availability of biosimilars can expand market access by lowering costs, potentially increasing the overall number of patients treated.

Key Market Restraints:

• Patent Expiration and Biosimilar Competition: This is the most significant restraint, leading to direct competition and price erosion.
• Alternative Therapies: The development of novel oral therapies for ITP and the shift away from interferon-based HCV treatment diminish the exclusive demand for Nplate. For example, thrombopoietin receptor agonists like eltrombopag (Promacta/Revolade) and avatrombopag (Doptelet) offer oral administration and are significant competitors in the ITP space.
• Cost and Reimbursement Pressures: Healthcare systems globally are under pressure to control drug spending. Payer negotiations and formulary restrictions can limit access to high-cost therapies, including originator biologics and even biosimilars.
• Administration Route: The subcutaneous injection route for Nplate, while effective, is less convenient than oral alternatives like eltrombopag or avatrombopag for chronic ITP management.

What are the Long-Term Price Projections?

Long-term price projections for Nplate are characterized by a sharp decline from current levels, followed by stabilization at a significantly lower point once biosimilar competition matures.

• 2025-2027: Prices for Nplate are projected to decrease by 20-40% as the first biosimilars enter the market. Biosimilar prices will likely be 20-30% below Nplate's current WAC.
• 2028-2030: Further price erosion is expected, with Nplate prices potentially falling by 40-60% from pre-biosimilar levels. This is driven by increased competition from multiple biosimilars, averaging 30-45% discounts to the originator.
• Post-2030: The price of Nplate will likely stabilize, albeit at a much lower price point, competing directly with biosimilars. The overall market for romiplostim will be driven by volume rather than high per-unit prices. The price will be dictated by the competitive landscape of approved romiplostim biosimilars.

These projections assume a standard market entry pattern for biosimilars. The actual pricing will be influenced by the number of biosimilar competitors, their respective manufacturing costs, and the strategic pricing decisions of both the originator and biosimilar manufacturers.

Key Takeaways

• Nplate's key composition of matter patents are expiring, notably U.S. Patent 7,538,097 in May 2024, opening the market to biosimilar competition.
• While no romiplostim biosimilars are currently FDA-approved, their market entry is anticipated within the next 1-3 years, leading to significant price erosion and market share loss for Nplate.
• Projections indicate a 20-40% price reduction for Nplate in the immediate post-biosimilar entry period, escalating to 40-60% by 2030.
• Oral thrombopoietin receptor agonists (eltrombopag, avatrombopag) represent existing competitive threats in the ITP market, limiting Nplate's pricing power and market share even before biosimilar entry.
• The market size for romiplostim (originator and biosimilars) may see initial growth due to increased access, but the originator's revenue will decline substantially.

Frequently Asked Questions

1. When will the last major patent protecting Nplate expire, enabling full generic/biosimilar market entry without significant patent barriers? The '725 and '097 patents, covering the composition of matter, are critical. Patent 7,538,097 expires in May 2024. However, additional patents covering manufacturing processes and methods of use, such as patent 9,056,852 (expiring February 2033), may extend effective market exclusivity through litigation or licensing. A comprehensive review of all active patents and their interplay is necessary for precise forecasting.

2. What is the expected price reduction percentage for Nplate once biosimilars are available? Initial price reductions of 20-40% are projected in the first 1-3 years following biosimilar entry. This erosion is expected to reach 40-60% by 2030 as competition intensifies among multiple biosimilars.

3. Are there any approved biosimilars for Nplate currently in the U.S. or EU markets? As of early 2024, there are no FDA-approved biosimilars for Nplate (romiplostim). Regulatory approval pathways and patent challenges are ongoing considerations for potential biosimilar developers.

4. What impact will the shift from interferon-based therapy for Hepatitis C have on Nplate demand? The widespread adoption of direct-acting antivirals (DAAs) for Hepatitis C has significantly reduced the reliance on interferon-based regimens. This has consequently diminished Nplate's role as an enabler for HCV treatment, impacting its demand in this specific indication.

5. Besides biosimilars, what are the other major competitive threats to Nplate in the ITP market? Oral thrombopoietin receptor agonists such as eltrombopag (Promacta/Revolade) and avatrombopag (Doptelet) are significant competitors in the ITP space. Their oral administration offers a convenience advantage over Nplate's subcutaneous injection, influencing physician and patient choice.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases (Specific drug approval information is accessed via FDA databases, not a direct URL for romiplostim).

[2] European Medicines Agency. (n.d.). EudraGMDP. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/nplate (Accessed for European approval information).

[3] U.S. Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov/ (Accessed for patent details and expiration dates).

[4] Amgen Inc. (2023). Annual Report on Form 10-K. Securities and Exchange Commission. (Accessed for company financial performance and product information).

[5] IQVIA. (Various Years). Market Analysis Reports. (Proprietary market data and analysis).

[6] EvaluatePharma. (Various Years). Drug and Market Analysis. (Proprietary pharmaceutical market intelligence).